Titan Pharmaceuticals

$3.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-1.85%) Today
+$0.06 (+1.88%) As of 10:10 AM UTC after-hours

Why Robinhood?

You can buy or sell TTNP and other stocks, options, and ETFs commission-free!

About TTNP

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA. The listed name for TTNP is Titan Pharmaceuticals, Inc. Common Stock.

CEO
Sunil Bhonsle, MBA
Employees
21
Headquarters
South San Francisco, California
Founded
1992
Market Cap
21.40M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.58M
High Today
$3.27
Low Today
$3.16
Open Price
$3.22
Volume
922.42K
52 Week High
$16.35
52 Week Low
$2.82

Collections

TTNP Earnings

-$0.38
-$0.25
-$0.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 30, Pre-Market

You May Also Like

EMDV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure